Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Imatinib mesylate has anti-inflammatory properties ... A group of mice were treated with either 33 mg/kg or 100 mg/kg imatinib (which produced blood levels similar to a mid-range dose in humans ...

Nilotinib in imatinib mesylate-resistant or intolerant accelerated chronic myeloid leukemia. A Phase II trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...